Benjamin Haibe-Kains , PhD

Follow Dr. Haibe-Kains:
Senior Scientist, Princess Margaret Cancer Centre
https://orcid.org/0000-0002-7684-0079
Keywords: bioinformatics, cancer, genomics, pharmacogenomics, translational research, machine learning
The research performed in the Haibe-Kains Laboratory focuses on the integration of high-throughput data from various sources to simultaneously analyze multiple facets of diseases, with a particular emphasis on cancer. Dr. Haibe-Kains and his team are using publicly available genomic datasets and data generated through his collaboration to better understand the biology underlying diseases and to develop new predictive models in order to significantly improve disease management. Dr. Haibe-Kains's main contributions include several prognostic gene signatures in breast cancer, subtype classification models for ovarian and breast cancers, as well as genomic predictors of drug response in cancer cell lines.

Related Links

Lab Website
Gene Expression Analyses in Breast Cancer: Sample Matters.
JNCI Cancer Spectr. 2018 Apr;2(2):pky019
Haibe-Kains B, Cescon DW
MetaGxData: Clinically Annotated Breast, Ovarian and Pancreatic Cancer Datasets and their Use in Generating a Multi-Cancer Gene Signature.
Sci Rep. 2019 Jun 19;9(1):8770
Gendoo DMA, Zon M, Sandhu V, Manem VSK, Ratanasirigulchai N, Chen GM, Waldron L, Haibe-Kains B
Why imaging data alone is not enough: AI-based integration of imaging, omics, and clinical data.
Eur J Nucl Med Mol Imaging. 2019 Jun 15;:
Holzinger A, Haibe-Kains B, Jurisica I
SIGN: Similarity identification in gene expression.
Bioinformatics. 2019 Jun 14;:
Madani Tonekaboni SA, Kumar Manem VS, El-Hachem N, Haibe-Kains B
Integrative pharmacogenomics analysis of patient-derived xenografts.
Cancer Res. 2019 May 29;:
Mer AS, Ba-Alawi W, Smirnov P, Wang YX, Brew B, Ortmann J, Tsao MS, Cescon DW, Goldenberg A, Haibe-Kains B
Meta-Analysis of 1,200 Transcriptomic Profiles Identifies a Prognostic Model for Pancreatic Ductal Adenocarcinoma.
JCO Clin Cancer Inform. 2019 May;3:1-16
Sandhu V, Labori KJ, Borgida A, Lungu I, Bartlett J, Hafezi-Bakhtiari S, Denroche RE, Jang GH, Pasternack D, Mbaabali F, Watson M, Wilson J, Kure EH, Gallinger S, Haibe-Kains B
AXL knockdown gene signature reveals a drug repurposing opportunity for a class of antipsychotics to reduce growth and metastasis of triple-negative breast cancer.
Oncotarget. 2019 Mar 12;10(21):2055-2067
Goyette MA, Cusseddu R, Elkholi I, Abu-Thuraia A, El-Hachem N, Haibe-Kains B, Gratton JP, Côté JF
An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).
J Immunother Cancer. 2019 Mar 13;7(1):72
Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S,...
Dr.VAE: Improving drug response prediction via modeling of drug perturbation effects.
Bioinformatics. 2019 Mar 08;:
Rampášek L, Hidru D, Smirnov P, Haibe-Kains B, Goldenberg A
A Comparative Study of Cluster Detection Algorithms in Protein-Protein Interaction for Drug Target Discovery and Drug Repurposing.
Front Pharmacol. 2019;10:109
Ma J, Wang J, Ghoraie LS, Men X, Haibe-Kains B, Dai P

Pages


 

Senior Scientist, Princess Margaret Cancer Centre

Scientific Lead, Data Science Program, Princess Margaret Cancer Center, University Health Network
Scientific Lead, Radiomics Program of the Radiation Medicine Program (RMP), Princess Margaret Cancer Center, University Health Network
Associate Professor, Department of Medical Biophysics, University of Toronto
Adjunct Professor, Department of Computer Science, University of Toronto
Faculty Associate, Ontario Institute of Cancer Research
Faculty Affiliate, Vector Institute